Eli Lilly and Co
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)
- Conditions
- Colorectal Carcinoma
- Interventions
- First Posted Date
- 2011-01-31
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT01286818
- Locations
- π―π΅
ImClone Investigational Site, Shizuoka, Japan
A Study of LY2801653 in Advanced Cancer
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 190
- Registration Number
- NCT01285037
- Locations
- πΊπΈ
Arizona Cancer Center, Tucson, Arizona, United States
πΊπΈMount Sinai Medical Center, New York, New York, United States
πΊπΈFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Safety Study in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 234
- Registration Number
- NCT01284335
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yakima, Washington, United States
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
- Conditions
- Carcinoma of Urinary TractUrethral CarcinomaCarcinoma of UreterCarcinoma of Renal Pelvis
- Interventions
- First Posted Date
- 2011-01-25
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 148
- Registration Number
- NCT01282463
- Locations
- π¨π¦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada
Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects
- Conditions
- Healthy Volunteers
- Interventions
- Drug: LY2452473
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT01275157
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
A Study of the Effect of LY2216684 on Lorazepam
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT01275144
- Locations
- π¬π§
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Leeds, United Kingdom
A Study of LY2216684 and Digoxin in Healthy Subjects
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2018-10-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT01266590
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States
A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: LY2216684Drug: albuterolDrug: propranololDrug: placebo for LY2216684Drug: placebo for albuterolDrug: placebo for propranolol
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT01263197
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States
A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT01263223
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States
A Study of LY2216684 and Theophylline in Healthy Subjects
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 21
- Registration Number
- NCT01263106
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States